Table 4.

Factors associated with recommended treatments in 2014.

	No/other	Bronchodilator therapy OR (95% CI)	p	LABA/ICS only OR (95% CI)	p	Triple inhaled therapy OR (95% CI)	p
Female sex	Ref	1.62	0.012	1.37	0.133	2.13	<0.0001
		(1.11 to 2.35)		(0.91 to 2.06)		(1.56 to 2.91)
Age	Ref	1.03	0.100	1.00	0.803	1.02	0.180
		(1.00 to 1.06)		(0.97 to 1.03)		(0.99 to 1.04)
High education	Ref	0.80	0.313	1.03	0.909	0.70	0.063
		(0.51 to 1.24)		(0.64 to 1.64)		(0.48 to 1.02)
Underweight	Ref	0.45	0.109	1.58	0.297	1.02	0.966
		(0.17 to 1.20)		(0.67 to 3.73)		(0.50 to 2.09)
Overweight	Ref	0.44	0.001	0.66	0.058	0.62	0.019
		(0.28 to 0.70)		(0.39 to 1.10)		(0.41 to 0.93)
Obesity	Ref	0.56	0.025	0.79	0.405	0.72	0.140
		(0.34 to 0.93)		(0.45 to 1.39)		(0.47 to 1.11)
Frequent exacerbations	Ref	1.31	0.254	2.02	0.004	2.34	<0.0001
		(0.83 to 2.06)		(1.26 to 3.25)		(1.62 to 3.36)
Higher CAT score	Ref	1.03	0.040	1.04	0.002	1.07	<0.0001
		(1.00 to 1.05)		(1.02 to 1.07)		(1.05 to 1.09)
Current daily smoking	Ref	0.64	0.039	0.37	<0.0001	0.40	<0.0001
		(0.42 to 0.98)		(0.23 to 0.62)		(0.28 to 0.57))
Specific responsible doctor	Ref	2.77	<0.0001	1.70	0.014	1.95	<0.0001
		(1.89 to 4.05)		(1.12 to 2.60)		(1.41 to 2.69)

Multinomial logistic regression of the three major recommended treatments. No/other includes patients with only rescue medication and with only ICS. Bronchodilator therapy includes maintenance treatment with long- or short-acting muscarinic antagonists and/or long-acting beta-2-agonists. LABA = long-acting beta-2-agonists; ICS = inhaled corticosteroids; CAT = COPD Assessment Test; OR = odds ratio; CI = confidence interval; Ref = reference category.